```
{
   "discriminator": "http://vocab.lappsgrid.org/ns/media/json",
   "payload": {
       "body": "Which 2 medications are included in the Qsymia pill?",
       "documents": [
           "http://www.ncbi.nlm.nih.gov/pubmed/23590816",
           "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
           "http://www.ncbi.nlm.nih.gov/pubmed/24222976",
           "http://www.ncbi.nlm.nih.gov/pubmed/23565717",
           "http://www.ncbi.nlm.nih.gov/pubmed/25826792",
           "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
           "http://www.ncbi.nlm.nih.gov/pubmed/23039320",
           "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
           "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
           "http://www.ncbi.nlm.nih.gov/pubmed/23625271",
           "http://www.ncbi.nlm.nih.gov/pubmed/24986038"
       ],
       "triples": [
           {
               "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
               "s": "http://linkedlifedata.com/resource/umls/id/C0013227",
               "o": "http://linkedlifedata.com/resource/umls/label/A18591068"
           },
           {
               "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
               "s": "http://linkedlifedata.com/resource/umls/label/A18591068",
               "o": "pharmaceutical preparations"
           },
           {
               "p": "http://www.w3.org/2000/01/rdf-schema#label",
               "s": "http://linkedlifedata.com/resource/umls/id/C0025118",
               "o": "medicine"
           },
           {
               "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
               "s": "http://linkedlifedata.com/resource/umls/id/C0013227",
               "o": "http://linkedlifedata.com/resource/umls/label/A18628198"
           },
           {
               "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
               "s": "http://linkedlifedata.com/resource/umls/label/A18628198",
               "o": "pharmaceutical preparation"
           },
           {
               "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
               "s": "http://linkedlifedata.com/resource/umls/id/C0013227",
               "o": "http://linkedlifedata.com/resource/umls/label/A18683808"
           },
           {
               "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
               "s": "http://linkedlifedata.com/resource/umls/label/A18683808",
               "o": "medications"
           },
           {
               "p": "http://www.w3.org/2000/01/rdf-schema#label",
               "s": "http://linkedlifedata.com/resource/umls/id/C0013227",
               "o": "drug"
           }
       ],
       "ideal_answer": [
           "Qsymia pill includes phentermine and topiramate. It is used for treatment of obesity."
       ],
       "exact_answer": [
           [
               "phentermine"
           ],
           [
               "topiramate"
           ]
       ],
       "type": "list",
       "id": "589a246c78275d0c4a000032",
       "snippets": [
           {
               "offsetInBeginSection": 235,
               "offsetInEndSection": 397,
               "text": "OBJECTIVE: To quantify the incremental cost-effectiveness of Qsymia (phentermine and topiramate extended-release) for health-related quality of life improvements.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 807,
               "offsetInEndSection": 1002,
               "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 449,
               "offsetInEndSection": 698,
               "text": "These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave), phentermine + topiramate (Qsymia), higher doses of existing drugs licensed for other indications (liraglutide, 3 mg), and new entities (lorcaserin).",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 593,
               "offsetInEndSection": 960,
               "text": "RECENT FINDINGS: Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 769,
               "offsetInEndSection": 982,
               "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 0,
               "offsetInEndSection": 326,
               "text": "After a long period of failure in development, two new medications (phentermine/topiramate ER - Qsymia\u2122 and lorcaserin - Belviq\u00ae) have been approved by the US Food and Drug Administration for long-term weight management in persons with obesity (BMI \u2265 30 kg/m(2)) or in overweight persons (BMI \u2265 27 kg/m(2)) with comorbidities.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/23625271",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 758,
               "offsetInEndSection": 952,
               "text": "The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5\u00a0mg plus topiramate 46.0\u00a0mg) vs. control, which included diet and lifestyle advice plus placebo",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/24986038",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 494,
               "offsetInEndSection": 924,
               "text": "Current antiobesity medications and pharmacological strategies will be reviewed.Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 631,
               "offsetInEndSection": 917,
               "text": "Almost a decade after the Food and Drug Administration approved the first weight loss medication, it recently approved two novel anti-obesity drugs Belviq (lorcaserin) and Qsymia (topiramate and phentermine), thus signalling the beginning of a new era in the pharmacotherapy of obesity.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/25826792",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 392,
               "offsetInEndSection": 865,
               "text": "Obesity is a public health crisis affecting approximately more than 33% of Americans and costing the healthcare system more than $190 billion annually.To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.Lifestyle modification is the first and mainstay treatment for obesity.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 774,
               "offsetInEndSection": 987,
               "text": "Adding to the current available pharmacotherapies for obesity, the Food and Drug Administration has recently approved 2 new combination medications known as lorcaserin (Belviq) and phentermine-topiramate (Qsymia).",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531960",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 575,
               "offsetInEndSection": 925,
               "text": "Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity.",
               "beginSection": "abstract",
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
               "endSection": "abstract"
           },
           {
               "offsetInBeginSection": 544,
               "offsetInEndSection": 795,
               "text": "To review the 2 new drugs that were recently approved by the US Food and Drug Administration (FDA) for the treatment of obesity, lorcaserin HCl (Belviq) and phentermine/topiramate (Qsymia) and their potential impact on the treatment of obese patients.",
               "beginSection": "abstract", 
               "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991373",
               "endSection": "abstract"
           }
       ]
   }
}
```
